Resources

Selected
  • COVID-19
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)

1589 results found

2023 ∙ Taheri, S.

Efficacy and safety of booster vaccination against SARS-CoV-2 in dialysis and renal transplant patients: systematic review and meta-analysis

  • All age groups
  • COVID-19
  • Safety
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Joudeh, A. I. Lutf, A. Q. Mahdi, S. Tran, G.

Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: A systematic review

  • Adolescents
  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Wen, J. Liu, Q. Tang, D. He, J. Q.

Efficacy of BCG Vaccination against COVID-19: Systematic Review and Meta-Analysis of Randomized Controlled Trials

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Dou, D. Zhang, F. Deng, X. Ma, Y. Wang, S. Ji, X. Zhu, X. Wang, D. Zhang, S. Zhao, L.

Efficacy of COVID-19 vaccines in inflammatory bowel disease patients receiving anti-TNF therapy: A systematic review and meta-analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Meo, S. A. Aftab, S. Bayoumy, N. M. Meo, A. S.

Efficacy of Oxford-AstraZeneca (ChAdOx1 CoV-19) vaccine against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) cases, hospital admissions, type of variants, and deaths

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Yang, Z. R. Jiang, Y. W. Li, F. X. Liu, D. Lin, T. F. Zhao, Z. Y. Wei, C. Jin, Q. Y. Li, X. M. Jia, Y. X. Zhu, F. C. Yang, Z. Y. Sha, F. Feng, Z. J. Tang, J. L.

Efficacy of SARS-CoV-2 vaccines and the dose-response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Low
2023 ∙ Widhani, A. Hasibuan, A. S. Rismawati, R. Maria, S. Koesnoe, S. Hermanadi, M. I. Ophinni, Y. Yamada, C. Harimurti, K. Sari, A. N. L. Yunihastuti, E. Djauzi, S.

Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Josiah, B. O. Uzor, C. C. Duncan, B. A. Enebeli, E. C. Otoboyor, N. L.

Efficacy, safety, and public attitude toward COVID-19 vaccines: A systematic review

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
  • Acceptance
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Wu, Y. Pan, Y. Su, K. Zhang, Y. Jia, Z. Yi, J. Lv, H. Zhang, L. Xue, M. Cao, D. Jiang, J.

Elder and booster vaccination associates with decreased risk of serious clinical outcomes in comparison of Omicron and Delta variant: A meta-analysis of SARS-CoV-2 infection

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Fazlollahi, A. Zahmatyar, M. Shamekh, A. Motamedi, A. Seyedi, F. Seyedmirzaei, H. Mousavi, S. E. Nejadghaderi, S. A. Sullman, M. J. M. Kolahi, A. A. Arshi, S. Safiri, S.

Electroencephalographic findings post-COVID-19 vaccination: A systematic review of case reports and case series

  • All age groups
  • COVID-19
  • Safety
Methodological quality (AMSTAR 2):
Critically low
Loading...